companies / emmyon-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 3,009,3753.0M | ○ |
|---|---|---|
| founded | 2013 | |
| hq | Rochester, USA | |
| industry | unknown | |
| stage | series-b+ |
Emmyon develops biopharmaceuticals targeting age-related muscle decline (sarcopenia) and cancer-related cachexia. It serves geriatric patients and oncology patients losing muscle mass and function. Its small-molecule muscle-anabolic mechanism is a pathway that GLP-1 and existing oncology drugs leave untreated.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-01-01 | strategic | 1,990,0002.0M | null | ○ |
Google Analytics, Google Tag Manager, Sucuri, jQuery Migrate 3.4.1, DoubleClick Floodlight, OWL Carousel, WordPress, Bluehost, PHP, MySQL, jquery 3.7.1
| fact | status | src |
|---|---|---|
| Strategic, $2.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |